Protagonist Therapeutics
PTGX
315 hedge funds and large institutions have $6.18B invested in Protagonist Therapeutics in 2025 Q4 according to their latest regulatory filings, with 83 funds opening new positions, 97 increasing their positions, 103 reducing their positions, and 39 closing their positions.
1,764% more call options, than puts
Call options by funds: $85.2M | Put options by funds: $4.57M
113% more first-time investments, than exits
New positions opened: 83 | Existing positions closed: 39
32% more capital invested
Capital invested by funds: $4.7B → $6.18B (+$1.48B)
20% more funds holding in top 10
Funds holding in top 10: 10 → 12 (+2)
15% more funds holding
Funds holding: 275 → 315 (+40)
0.48% less ownership
Funds ownership: 113.62% → 113.14% (-0.48%)
6% less repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 103
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$127M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$103M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$94.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$72.7M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$71.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$170M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$114M |
| 3 |
JFG
Jefferies Financial Group
New York
|
-$66.8M |
| 4 |
RI
RTW Investments
New York
|
-$57.1M |
| 5 |
CC
Commodore Capital
New York
|
-$47.1M |
PTGX Hedge Fund Activity: Q4 2025 in Review
315 of the 8,266 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q4 2025, worth a combined $6.18B — up 32% from $4.7B a quarter earlier.
Buyers outnumbered sellers: 83 funds opened new PTGX positions and 39 closed out — a net gain of 44 holders — while 97 added to existing stakes and 103 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $127M. The largest seller was BVF Inc, exiting entirely with an estimated $170M sold.
- 315 institutional investors held Protagonist Therapeutics (PTGX) as of Q4 2025, up from 275 in Q3 2025.
- Funds reported $6.18B of Protagonist Therapeutics stock for Q4 2025, up 32% quarter-over-quarter.
- 83 funds opened new Protagonist Therapeutics positions in Q4 2025 and 39 closed out, a net change of +44 holders.
- The largest Protagonist Therapeutics buyer in Q4 2025 was Janus Henderson Group, an estimated $127M added.
- The largest Protagonist Therapeutics seller in Q4 2025 was BVF Inc, an estimated $170M sold.
Based on aggregated 13F filings for Q4 2025.